SSRIs and SNRIs for Management of Hot Flushing.
- Author:
Jae Yen SONG
1
;
Mee Ran KIM
;
Jang Heub KIM
Author Information
1. Department of Obstetrics and Gynecology, The Catholic University of Korea, School of Medicine, Seoul, Korea. janghkim@catholic.ac.kr
- Publication Type:Review ; Clinical Trial
- Keywords:
Hot flush;
Menopause;
Serotonin norepinephrine reuptake inhibitor;
Selective serotonin reuptake inhibitor
- MeSH:
Breast Neoplasms;
Citalopram;
Cyclohexanols;
Female;
Fluoxetine;
Flushing;
Humans;
Menopause;
Norepinephrine;
Paroxetine;
Quality of Life;
Risk Assessment;
Serotonin;
Serotonin Uptake Inhibitors;
Sertraline;
Tamoxifen;
Desvenlafaxine Succinate;
Venlafaxine Hydrochloride
- From:The Journal of Korean Society of Menopause
2011;17(2):68-74
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
For postmenopausal women who fear hormone therapy, women 60 years of age with continuous, severe hot flushing or women with a history of breast cancer, we should consider selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs) as therapeutic agents. Base on the results from a meta-analysis and clinical trials regarding hot flushing, paroxetine and the conetrolled-release formultation of paroxetine have been shown to effectively reduce hot flushing by 30~40% and 60~70%, respectively, and 13~41% more reductions as compared to placebo. Venlafaxine reduced hot flushes by 30~60% (133% reductions compared to placebo), and desvenlafaxine reduced hot flushes by 30~70%. Fluoxetine and citalopram were shown to be less effective than paroxetine and venlafaxine, by 20% (113% reductions compared to placebo) and 40~50%, respectively. Sertraline reduced hot flushes 3~18% compared to the placebo group, but was considered ineffective. Citalopram (20 mg), paroxetine (10 mg), venlafaxine (37.5~150 mg), and desvenlafaxine (100~200 mg) not only reduced vasomotor symptoms, but demonstrated additional beneficial outcomes with respect to sleep disturbances, mood, the vigor index, and improved quality of life. Citalopram (20 mg), fluoxetine (20 mg), paroxetine (10 mg), venlafaxine (75~150 mg), and desvenlafaxine (150 mg) are recommended at the corresponding doses after weighing the risks and benefits of these medications. SSRIs and SNRIs were shown to interrupt the conversion of tamoxifen into the active metabolite, endoxifen, and thus SSRIs and SNRIs must not be used in breast cancer patients who are taking tamoxifen. Paroxetine suppressed vasomotor symptoms most potently, followed by fluoxetine, sertraline, citalopram, and venlafaxine.
